FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386400537> ?p ?o ?g. }

• W4386400537 endingPage "115697" @default.
• W4386400537 startingPage "115697" @default.
• W4386400537 abstract "A few researches have reported the exposure-efficacy/toxicity relationships of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). On account of the large interpatient pharmacokinetic variability, therapeutic drug monitoring (TDM) seems promising for optimizing dosage regimen and improving treatment efficacy and safety. Therefore, a rapid and convenient ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the determination of icotinib, osimertinib, gefitinib and O-demesthyl gefitinib in human plasma for TDM.Icotinib-D4 and osimertinib-13CD3 were used as the internal standards (ISs). The samples were prepared by protein precipitation using acetonitrile. Chromatographic separation was achieved on a 40 ℃ Shimadzu Shim-pack Scepter C18-120 column (2.1 ×50 mm, 3.0 µm, Japan) by a Shimadzu 30 A solvent management system. Detection was carried out using a Shimadzu LC-MS 8050CL triple quadrupole mass spectrometer coupled with an electrospray ionization source in positive mode.This analytical method was fully validated with selectivity, carry-over, linearity, lower limit of quantification, accuracy (from 92.68% to 106.62%) and precision (intra- and inter-day coefficients of variation ranged from 0.92% to 9.85%), matrix effect, extraction recovery, stability and dilution integrity. The calibration curves were developed to be within the concentration ranges of 200-4000 ng/mL for icotinib, 50-1000 ng/mL for osimertinib, gefitinib and O-desmethyl gefitinib in human plasma which meet the needs of routine TDM.The proposed method was used in 100 patients with non-small cell lung cancer for monitoring plasma concentration of the mentioned EGFR-TKIs. The trough concentrations of ICO were distributed between 226.42 ng/mL and 3853.36 ng/mL, peak concentrations were between 609.20 ng/mL and 2191.54 ng/mL. The trough concentrations of OSI were distributed between 110.48 ng/mL and 1183.13 ng/mL. The trough concentrations of GEF were distributed between 117.71 ng/mL and 582.74 ng/mL, while DeGEF was distributed from 76.21 ng/mL to 1939.83 ng/mL with two less than 20 ng/mL. The results of therapeutic drug monitoring aimed to investigate exposure-efficacy/toxicity relationship and improve the efficacy and safety of targeted therapies." @default.
• W4386400537 created "2023-09-04" @default.
• W4386400537 creator A5000948146 @default.
• W4386400537 creator A5018918631 @default.
• W4386400537 creator A5031545775 @default.
• W4386400537 creator A5040806000 @default.
• W4386400537 creator A5044127384 @default.
• W4386400537 creator A5045810995 @default.
• W4386400537 creator A5049641684 @default.
• W4386400537 creator A5052626969 @default.
• W4386400537 creator A5057566040 @default.
• W4386400537 creator A5065014768 @default.
• W4386400537 creator A5077248564 @default.
• W4386400537 creator A5082090050 @default.
• W4386400537 creator A5083364618 @default.
• W4386400537 creator A5085447714 @default.
• W4386400537 date "2023-11-01" @default.
• W4386400537 modified "2023-10-16" @default.
• W4386400537 title "A fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS/MS for therapeutic drug monitoring" @default.
• W4386400537 cites W1998415923 @default.
• W4386400537 cites W2044927870 @default.
• W4386400537 cites W2045652732 @default.
• W4386400537 cites W2063851889 @default.
• W4386400537 cites W2112988953 @default.
• W4386400537 cites W2130106644 @default.
• W4386400537 cites W2315113295 @default.
• W4386400537 cites W2345489434 @default.
• W4386400537 cites W2565691474 @default.
• W4386400537 cites W2603314840 @default.
• W4386400537 cites W2921458278 @default.
• W4386400537 cites W2946393465 @default.
• W4386400537 cites W2951462508 @default.
• W4386400537 cites W3036459244 @default.
• W4386400537 cites W3134553072 @default.
• W4386400537 cites W4211059596 @default.
• W4386400537 cites W4296803498 @default.
• W4386400537 cites W4310603646 @default.
• W4386400537 cites W4317941487 @default.
• W4386400537 doi "https://doi.org/10.1016/j.jpba.2023.115697" @default.
• W4386400537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37713984" @default.
• W4386400537 hasPublicationYear "2023" @default.
• W4386400537 type Work @default.
• W4386400537 citedByCount "0" @default.
• W4386400537 crossrefType "journal-article" @default.
• W4386400537 hasAuthorship W4386400537A5000948146 @default.
• W4386400537 hasAuthorship W4386400537A5018918631 @default.
• W4386400537 hasAuthorship W4386400537A5031545775 @default.
• W4386400537 hasAuthorship W4386400537A5040806000 @default.
• W4386400537 hasAuthorship W4386400537A5044127384 @default.
• W4386400537 hasAuthorship W4386400537A5045810995 @default.
• W4386400537 hasAuthorship W4386400537A5049641684 @default.
• W4386400537 hasAuthorship W4386400537A5052626969 @default.
• W4386400537 hasAuthorship W4386400537A5057566040 @default.
• W4386400537 hasAuthorship W4386400537A5065014768 @default.
• W4386400537 hasAuthorship W4386400537A5077248564 @default.
• W4386400537 hasAuthorship W4386400537A5082090050 @default.
• W4386400537 hasAuthorship W4386400537A5083364618 @default.
• W4386400537 hasAuthorship W4386400537A5085447714 @default.
• W4386400537 hasConcept C112705442 @default.
• W4386400537 hasConcept C162356407 @default.
• W4386400537 hasConcept C170493617 @default.
• W4386400537 hasConcept C175467004 @default.
• W4386400537 hasConcept C185592680 @default.
• W4386400537 hasConcept C2777477808 @default.
• W4386400537 hasConcept C2777626846 @default.
• W4386400537 hasConcept C2778087573 @default.
• W4386400537 hasConcept C2779438470 @default.
• W4386400537 hasConcept C2780272996 @default.
• W4386400537 hasConcept C2780580887 @default.
• W4386400537 hasConcept C2780837634 @default.
• W4386400537 hasConcept C43617362 @default.
• W4386400537 hasConcept C55493867 @default.
• W4386400537 hasConcept C64489805 @default.
• W4386400537 hasConcept C71924100 @default.
• W4386400537 hasConcept C74774607 @default.
• W4386400537 hasConcept C98274493 @default.
• W4386400537 hasConceptScore W4386400537C112705442 @default.
• W4386400537 hasConceptScore W4386400537C162356407 @default.
• W4386400537 hasConceptScore W4386400537C170493617 @default.
• W4386400537 hasConceptScore W4386400537C175467004 @default.
• W4386400537 hasConceptScore W4386400537C185592680 @default.
• W4386400537 hasConceptScore W4386400537C2777477808 @default.
• W4386400537 hasConceptScore W4386400537C2777626846 @default.
• W4386400537 hasConceptScore W4386400537C2778087573 @default.
• W4386400537 hasConceptScore W4386400537C2779438470 @default.
• W4386400537 hasConceptScore W4386400537C2780272996 @default.
• W4386400537 hasConceptScore W4386400537C2780580887 @default.
• W4386400537 hasConceptScore W4386400537C2780837634 @default.
• W4386400537 hasConceptScore W4386400537C43617362 @default.
• W4386400537 hasConceptScore W4386400537C55493867 @default.
• W4386400537 hasConceptScore W4386400537C64489805 @default.
• W4386400537 hasConceptScore W4386400537C71924100 @default.
• W4386400537 hasConceptScore W4386400537C74774607 @default.
• W4386400537 hasConceptScore W4386400537C98274493 @default.
• W4386400537 hasLocation W43864005371 @default.
• W4386400537 hasLocation W43864005372 @default.
• W4386400537 hasOpenAccess W4386400537 @default.
• W4386400537 hasPrimaryLocation W43864005371 @default.

• next